Policy

The politicization of public health is eroding vaccine confidence, risking lower uptake and potential disease outbreaks, says Noel T. Brewer, PhD.

Experts unpacked MFN drug pricing, expired ACA subsidies, and IRA fallout for community oncology in a recent webinar.

Medicaid managed care organizations should prioritize children in low-opportunity neighborhoods to optimize health care utilization, improve minority health, and address health-related social needs.

The Inflation Reduction Act introduced Medicare drug price negotiations to reduce treatment costs, enhance access, and potentially reshape prescribing patterns in oncology and hematology.

A study of 1.5 million patients suggests that ACA Medicaid expansion reduces breast cancer deaths, especially advanced cases—yet racial and income gaps persist.

Bidisha Mandal, PhD, concluded her conversation with AJMC by emphasizing the need for policy support and further research to maximize telehealth's impact.

A new science-focused autism committee mobilizes against controversial federal appointments.

Jody L. Green, PhD, explains how regulatory decisions shape medication safety amid uptake of OTC drugs.

Socioeconomic adversity in the perinatal period drives widening low birth weight gaps, fueling adverse pregnancy outcomes and deepening maternal and infant health inequities.

Nearly 3 million MA enrollees may lose plan coverage in 2026 as payment reforms drive market exits, hitting rural areas hardest and reshaping competition, explains Mark Meiselbach, PhD.

340B covered entities are expanding contracts with retail pharmacies that are increasingly located in counties with high rates of Medicare and Medicaid insurance coverage.

Sweeping federal funding cuts and stalled prevention efforts are unraveling hard-won gains in HIV research and access, warns Peter Staley.

Kevin Ma, PhD, discusses new data showing 2024–2025 COVID-19 vaccines reduced hospitalization and severe outcomes.

The authors argue that sustainable drug pricing reform should focus on patient-centered value, not price alone.

Over 15,000 NYC nurses ratified new contracts after a 41-day strike, securing staffing protections, salary increases, and safety reforms.

MA grocery card use was associated with modest increases in wellness, primary care, and specialist visits among dual-eligible beneficiaries, says Jennifer L. Kowalski, MS.

New research shows that adherence to antiretroviral therapy and pre-exposure prophylaxis depends on a steady budget through PEPFAR and SNAP.

The authors discuss ways to ensure that accountable care organizations do not bear the cost of inaccurate spending growth predictions.

The first full day of CROI 2026 featured a lecture that outlined the next steps in treating and preventing HIV.

Kavita Nair, PhD, discusses how clinicians select MS therapies, the role of cost and access, and why policy changes could threaten patient outcomes.

From clinic closures to gene therapy costs, new data reveal how policy, prices, and structural racism reshape US health access and outcomes.

Reform priorities aim to reshape PBM oversight, delink compensation from drug prices, boost transparency, and protect pharmacy access.

A commentary by FDA officials Vinay Prasad, MD, MPH, and Martin Makary, MD, MPH, details the new system for drug approvals in the US.

Updated NCCN pediatric STS guidelines emphasize risk stratification, imaging, multimodal therapy, and clinical trial enrollment to improve outcomes.

Medicare Advantage beneficiaries face forced disenrollment in 2026 as plan exits drive coverage termination, pushing millions toward traditional Medicare and Part D’s $2100 cap.